Pharmacogenetics is becoming increasingly relevant in the diagnosis, treatment, and recovery of cancer patients. A major problem facing oncologists is the outstanding varied efficacy of treatment. Promising advances in pharmacogenetics have allowed the development of effective agents which will enable personalized cancer chemotherapy to become routine for the clinical practice.
Pharmacogenetics is becoming increasingly relevant in the diagnosis, treatment, and recovery of cancer patients. A major problem facing oncologists is the outstanding varied efficacy of treatment. Promising advances in pharmacogenetics have allowed the development of effective agents which will enable personalized cancer chemotherapy to become routine for the clinical practice.
Brian Leyland-Jones (Winship Cancer Institute, Emory University, Atlanta, Georgia) (Edited by)
Inhaltsangabe
Pharmacogenomic approaches. Individualized kinetics and dosing. Clasical IHC and FISH state of the art. Affy-based chemo and dosing. Panoply of genomic approaches. Epigenetics. Illumina-based platforms. Proteomics. Measurement of Pharmacodynamic endpoints. What tissues are needed + specimen collection
Pharmacogenomic approaches. Individualized kinetics and dosing. Clasical IHC and FISH state of the art. Affy-based chemo and dosing. Panoply of genomic approaches. Epigenetics. Illumina-based platforms. Proteomics. Measurement of Pharmacodynamic endpoints. What tissues are needed + specimen collection
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Shop der buecher.de GmbH & Co. KG Bürgermeister-Wegele-Str. 12, 86167 Augsburg Amtsgericht Augsburg HRA 13309